Hyderabad Genome Valley to host Aurigene Pharmaceutical’s Rs 330 crore-facility
The step-down subsidiary of Dr. Reddy's Laboratories, Aurigene Pharmaceutical services Ltd, has made the decision to build a cutting-edge development and manufacturing facility in hyderabad that will concentrate on specialized markets like therapeutic proteins, antibodies, and viral vectors.
On Tuesday, IT and industries minister KT Rama Rao met with Satish Reddy, Chairman of Dr. Reddy's Laboratories, and akhil Ravi, Chief Executive Officer of Aurigene Pharmaceuticals services Limited, to discuss the new facility and Aurigene's expansion plans for Hyderabad. They claimed that the main goal of the US$ 40 million (about Rs. 330 crores) investment was to create employment opportunities. Within the next three years of the present investment plans, they expect to generate about 200 direct job roles and additional 60–70 indirect work opportunities.
The business also foresees a considerable scaling up of its investments in the future, which would lead to a multiplicity of new job opportunities in extremely cutting-edge industrial and scientific fields. According to a formal statement, Aurigene also has development ambitions for the facility that involves foraying into innovative therapeutics, notably cell, and gene therapies.
"I'm thrilled that Aurigene chose Genome Valley for the construction of their cutting-edge R&D and manufacturing facilities. The State government's mission to improve "complex manufacturing at scale," with the goal of making a significant advancement in therapeutic modalities, is perfectly linked with this investment. The minister stated that by investing in biotherapeutics discovery, Aurigene has furthered Hyderabad's position as a top location for biopharmaceutical research and production. The minister also stated that Aurigene's investment would support the State government's goal to advance and promote the biologics capabilities of the State by helping to expand the biotherapeutics contract Development and Manufacturing Organisation (CDMO) ecosystem in Hyderabad.
"We appreciate the telangana government's efforts to transform hyderabad and telangana into a major centre for pharmaceutical and biotechnology research and development by bringing together numerous stakeholders and providing essential infrastructure. As part of our ongoing efforts to provide top-notch services to biotech firms worldwide, we are thrilled to extend our infrastructure in Genome Valley (Hyderabad), stated akhil Ravi, Chief Executive Officer of Aurigene Pharmaceuticals services Limited.
"I'm thrilled that Aurigene chose Genome Valley for the construction of their cutting-edge R&D and manufacturing facilities. The State government's mission to improve "complex manufacturing at scale," with the goal of making a significant advancement in therapeutic modalities, is perfectly linked with this investment. The minister stated that by investing in biotherapeutics discovery, Aurigene has furthered Hyderabad's position as a top location for biopharmaceutical research and production. The minister also stated that Aurigene's investment would support the State government's goal to advance and promote the biologics capabilities of the State by helping to expand the biotherapeutics contract Development and Manufacturing Organisation (CDMO) ecosystem in Hyderabad.
"We appreciate the telangana government's efforts to transform hyderabad and telangana into a major centre for pharmaceutical and biotechnology research and development by bringing together numerous stakeholders and providing essential infrastructure. As part of our ongoing efforts to provide top-notch services to biotech firms worldwide, we are thrilled to extend our infrastructure in Genome Valley (Hyderabad), stated akhil Ravi, Chief Executive Officer of Aurigene Pharmaceuticals services Limited.